Key result
VEGF signaling pathway inhibitors commonly induce systemic hypertension as an on-target effect, which is generally manageable with standard antihypertensives and rarely requires treatment cessation.
This review highlights systemic hypertension as the most common cardiovascular side effect of VEGF inhibitors in cancer patients and discusses its incidence, mechanisms, and management.
Supports vigilant BP monitoring with VSP inhibitors; extends mechanistic understanding but leaves optimal strategies open.
New anti-cancer drugs that inhibit the vascular endothelial growth factor (VEGF) signaling pathway are highly effective in the treatment of solid tumors, however concerns remain regarding their cardiovascular safety. The most common side effect of VEGF signaling pathway (VSP) inhibition is the development of systemic hypertension. We review the incidence, possible mechanisms, significance and management of hypertension in patients treated with VSP inhibitors.
No takes yet. Share an insight, caveat, or question.
Wasserstrum et al. (2015) conducted a review in Cancer. VEGF signaling pathway (VSP) inhibitors was evaluated. VEGF signaling pathway inhibitors commonly induce systemic hypertension as an on-target effect, which is generally manageable with standard antihypertensives and rarely requires treatment cessation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: